title: Quantitative whole-body MRI in familial partial lipodystrophy type 2: changes in adipose tissue distribution coincide with biochemical improvement.
abstract: OBJECTIVE
  Familial partial lipodystrophy type 2 (Online Mendelian Inheritance in Man no. 151660) is a systemic disorder characterized by regional lipoatrophy and lipohypertrophy, severe insulin resistance, and early cardiovascular death. At initial presentation, whole-body MRI allows the radiologist to accurately characterize patients with familial partial lipodystrophy and helps differentiate familial partial lipodystrophy from many other subtypes of lipodystophy. We present the findings of serial quantitative MRI analysis in two patients with familial partial lipodystrophy type 2 and outline the objective imaging changes that occur during medical therapy with oral rosiglitazone.
  
  
  CONCLUSIONS
  Cervical adipose volume and visceral adipose area increased by 105% and 60% in the two patients and hepatic fat fraction decreased by 55% during a 21-month period of medical therapy. These changes coincided with a decrease in biochemical indexes of insulin resistance. Whole body quantitative MRI may therefore help to demonstrate the subclinical changes in fat deposition that occur as a result of novel treatment of familial partial lipodystrophy and with continued research may play a role in guiding the choice, duration, and intensity of novel medical therapy.
authors.affiliation: Department of Radiology, Cork University Hospital, Wilton, Cork, Ireland.
authors.forename: Patrick D
authors.initials: PD
authors.lastname: McLaughlin
authors.forename: James
authors.initials: J
authors.lastname: Ryan
authors.forename: Phillip A
authors.initials: PA
authors.lastname: Hodnett
authors.forename: Domhnall
authors.initials: D
authors.lastname: O'Halloran
authors.forename: Michael M
authors.initials: MM
authors.lastname: Maher
mesh_terms: D000273:Adipose Tissue / Q000473:pathology*; D000293:Adolescent; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D052496:Lipodystrophy, Familial Partial / Q000188:drug therapy / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use; D051598:Whole Body Imaging
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone